Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

Lieng, Hester; Kneebone, Andrew; Hayden, Amy J.; Christie, David R. H.; Davis, Brian J.; Eade, Thomas N.; Emmett, Louise; Holt, Tanya; Hruby, George; Pryor, David; Sidhom, Mark; Skala, Marketa; Yaxley, John; Shakespeare, Thomas P.

Title: Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
Creator: Lieng, Hester; Kneebone, Andrew; Hayden, Amy J.; Christie, David R. H.; Davis, Brian J.; Eade, Thomas N.; Emmett, Louise; Holt, Tanya; Hruby, George; Pryor, David; Sidhom, Mark; Skala, Marketa; Yaxley, John; Shakespeare, Thomas P.
Relation: Radiotherapy and Oncology Vol. 140, p. 68-75
Publisher Link: http://dx.doi.org/10.1016/j.radonc.2019.05.016
Publisher: Elsevier Ireland
Resource Type: journal article
Date: 2019
Description: The management of node-positive prostate cancer is highly variable, with both locoregional and systemic treatment options available. With the increasing use of novel imaging techniques such as PSMA-PET and MRI, combined with the increasing use of surgery for high-risk prostate cancer, clinical and pathological regional nodal disease is being detected at a higher rate and at an earlier stage than previously. This creates a window for a potentially curative management approach. The role of radiotherapy including optimal radiation target volumes and dose, as well as the timing and duration of accompanying systemic therapy remains uncertain. At a workshop in 2017, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified variations in the management of node-positive prostate cancer identified on primary staging or on histopathology at radical prostatectomy. FROGG reviewed the literature and developed a set of evidence-based recommendations on the appropriate investigation and management of clinically and pathologically node-positive prostate cancer. These recommendations encompass imaging techniques, radiation treatment target volumes and doses, as well as the use of androgen deprivation therapy.
Subject: prostate cancer; nodal metastases; PSMA-PET; IMRT; SDG 3; Sustainable Development Goals
Identifier: http://hdl.handle.net/1959.13/1459124
Identifier: uon:45588
Identifier: ISSN:0167-8140
Language: eng
Reviewed

Hits: 5181
Visitors: 5174
Downloads: 1

Collections

Goal 3: Good Health and Well-Being

		Thumbnail	File	Description	Size	Format